Atara Biotherapeutics, Inc.

Atara Biotherapeutics develops therapies for solid tumors, hematologic cancers, and autoimmune diseases. Tab-cel, its lead product, is in Phase 3 trials for EBV-driven post-transplant lymphoproliferative disease and nasopharyngeal carcinoma. The company has a CAR T immunotherapy pipeline with ATA3219 and ATA3431 in clinical/trial stages. ATA188 is in Phase 2 trials to treat multiple sclerosis. Atara also collaborates with Memorial Sloan Kettering Cancer Center and Queensland Institute of Medical Research. The company was incorporated in 2012 and is headquartered in California.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

11.5 USD

Potential

-100%

Strengths

The company has high returns. ROIC (100.00%) is higher than the sector mean (6.02%).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	100.0%
Net Debt/EBITDA	100.0